Consensus-based approach for severe paediatric asthma in routine clinical practice

• Published in: Anales de pediatría (Barcelona, Spain : 2003) Vol. 84; no. 2; pp. 122.e1 - 122.e11
• Main Authors: Plaza, A M, Ibáñez, M D P, Sánchez-Solís, M, Bosque-García, M, Cabero, M J, Corzo, J L, García-Hernández, G, de la Hoz, B, Korta-Murua, J, Sánchez-Salguero, C, Torres-Borrego, J, Tortajada-Girbés, M, Valverde-Molina, J, Zapatero, L, Nieto, A
• Format: Journal Article
• Language: Spanish
• Published: Spain 01.02.2016
• Subjects: Adrenal Cortex Hormones - therapeutic use; Anti-Asthmatic Agents - therapeutic use; Asthma - drug therapy; Child; Consensus; Humans; Practice Guidelines as Topic; Quality of Life; Asma grave; Delphi technique; Técnica Delphi; Omalizumab; Asma; Pediatría; Severe asthma; Paediatrics; Asthma
• ISSN: 1695-9531
• DOI: 10.1016/j.anpedi.2015.08.015

Accurate identification of paediatric patients with severe asthma is essential for an adequate management of the disease. However, criteria for defining severe asthma and recommendations for control vary among different guidelines. An online survey was conducted to explore expert opinions about the definition and management of severe paediatric asthma. To reach a consensus agreement, a modified Delphi technique was used, and practice guidelines were prepared after the analysis of the results. Eleven paediatric chest disease physicians and allergy specialists with wide expertise in severe asthma responded to the survey. Consensus was reached in 50 out of 65 questions (76.92%). It was considered that a patient has severe asthma if during the previous year they have required 2 or more cycles of oral steroids, required daily treatment with medium doses of inhaled corticosteroids (with other controller medication) or high doses (with or without other controller medication), did not respond to optimised conventional treatment, or if the disease threatened the life of the patient or seriously impairs their quality of life. The definition of severe asthma may also include patients who justifiably use health resources on a regular basis, or have psychosocial or environmental factors impeding control. For monitoring, the use of questionnaires designed specifically for paediatric population, such as CAN or ACT, is recommended. As regards treatment, the use of omalizumab should be considered prior to the use of oral corticosteroids. This paper provides consensus recommendations that may be useful in the management of severe paediatric asthma.